Follow the people · Insider
Brad Hively
Brad Hively files insider transactions with the SEC as a director of Starling Oncology (STLN). We hold 1 disclosed purchase or sale filed since 16 November 2021, 1 of them in the last 90 days.
- Files forSTLN
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure24 August 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 21 August 2026 — 21 August 2026Director · Starling Oncology (STLN)1 Form 4 line · source: SEC Form 4
- Filed 12 January 2021 — 27 July 2026Chief Executive Officer · Oncology Institute (TOI)49 Form 4 lines · source: SEC Form 4
Everything they disclosed
50 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 298,853 shares of Starling OncologySEC Form 424 August 2026Common Stock · traded 21 August 2026 · filed 24 August 2026
- was granted 27,108 shares of Oncology InstituteSEC Form 429 July 2026Common Stock · traded 27 July 2026 · filed 29 July 2026
- ▼ sold on the open market 13,333 shares of Oncology InstituteSEC Form 416 December 2025Common Stock · traded 15 December 2025 · filed 16 December 2025
- was granted 41,667 shares of Oncology InstituteSEC Form 424 November 2025Common Stock · traded 20 November 2025 · filed 24 November 2025
- was granted 32,407 shares of Oncology InstituteSEC Form 424 November 2025Common Stock · traded 20 November 2025 · filed 24 November 2025
- ▼ sold on the open market 20,221 shares of Oncology InstituteSEC Form 421 August 2025Common stock · traded 19 August 2025 · filed 21 August 2025
- exercised options over 684,528 shares of Oncology Institute (a derivative holding)SEC Form 45 June 2025Non-Qualified Stock Option (right to buy) · traded 3 June 2025 · filed 5 June 2025
- exercised options over 105,320 shares of Oncology Institute (a derivative holding)SEC Form 45 June 2025Non-Qualified Stock Option (right to buy) · traded 3 June 2025 · filed 5 June 2025
- exercised options over 131,297 shares of Oncology Institute (a derivative holding)SEC Form 45 June 2025Non-Qualified Stock Option (right to buy) · traded 3 June 2025 · filed 5 June 2025
- exercised options over 946,460 shares of Oncology Institute (a derivative holding)SEC Form 45 June 2025Non-Qualified Stock Option (right to buy) · traded 3 June 2025 · filed 5 June 2025
- exercised options over 684,528 shares of Oncology InstituteSEC Form 45 June 2025Common Stock · traded 3 June 2025 · filed 5 June 2025
- exercised options over 105,320 shares of Oncology InstituteSEC Form 45 June 2025Common Stock · traded 3 June 2025 · filed 5 June 2025
- exercised options over 131,297 shares of Oncology InstituteSEC Form 45 June 2025Common Stock · traded 3 June 2025 · filed 5 June 2025
- exercised options over 946,460 shares of Oncology InstituteSEC Form 45 June 2025Common Stock · traded 3 June 2025 · filed 5 June 2025
- ▼ sold on the open market 1,867,605 shares of Oncology InstituteSEC Form 45 June 2025Common Stock · traded 3 June 2025 · filed 5 June 2025
- ▼ sold on the open market 108,532 shares of Oncology InstituteSEC Form 45 June 2025Common Stock · traded 3 June 2025 · filed 5 June 2025
- ▲ bought on the open market 22,640 shares of Oncology Institute (a derivative holding)SEC Form 428 April 2025Common Warrant · traded 26 March 2025 · filed 28 April 2025
- ▲ bought on the open market 45,280 shares of Oncology InstituteSEC Form 428 April 2025Common Stock · traded 26 March 2025 · filed 28 April 2025
- ▲ bought on the open market 4,528 shares of Oncology Institute (a derivative holding)SEC Form 428 March 2025Common Warrant · traded 26 March 2025 · filed 28 March 2025
- ▲ bought on the open market 9,056 shares of Oncology InstituteSEC Form 428 March 2025Common Stock · traded 26 March 2025 · filed 28 March 2025
- acquired or disposed of, other 353,450 shares of Oncology InstituteSEC Form 42 December 2024Common stock · traded 12 November 2024 · filed 2 December 2024
- ▲ bought on the open market 250,000 shares of Oncology InstituteSEC Form 42 December 2024Common stock · traded 26 November 2024 · filed 2 December 2024
- ▲ bought on the open market 50,000 shares of Oncology InstituteSEC Form 42 December 2024Common stock · traded 2 December 2024 · filed 2 December 2024
- was granted 44,000 shares of Oncology InstituteSEC Form 425 November 2024Common stock · traded 22 November 2024 · filed 25 November 2024
- returned to the issuer 18,121 shares of Oncology InstituteSEC Form 420 June 2024Common Stock · traded 17 June 2024 · filed 20 June 2024
- returned to the issuer 19,526 shares of Oncology InstituteSEC Form 423 May 2024Common Stock · traded 22 May 2024 · filed 23 May 2024
- was granted 42,652 shares of Oncology InstituteSEC Form 428 December 2023Common stock · traded 26 December 2023 · filed 28 December 2023
- returned to the issuer 25,867 shares of Oncology InstituteSEC Form 422 November 2023Common stock · traded 21 November 2023 · filed 22 November 2023
- exercised options over 25,000 shares of Oncology Institute (a derivative holding)SEC Form 421 November 2023Non-Qualified Stock Option (right to buy) · traded 17 November 2023 · filed 21 November 2023
- exercised options over 25,000 shares of Oncology InstituteSEC Form 421 November 2023Common stock · traded 17 November 2023 · filed 21 November 2023
- ▼ sold on the open market 25,000 shares of Oncology InstituteSEC Form 421 November 2023Common stock · traded 17 November 2023 · filed 21 November 2023
- exercised options over 47,000 shares of Oncology Institute (a derivative holding)SEC Form 415 November 2023Non-Qualified Stock Option (right to buy) · traded 13 November 2023 · filed 15 November 2023
- exercised options over 47,000 shares of Oncology InstituteSEC Form 415 November 2023Common stock · traded 13 November 2023 · filed 15 November 2023
- ▼ sold on the open market 47,000 shares of Oncology InstituteSEC Form 415 November 2023Common stock · traded 13 November 2023 · filed 15 November 2023
- returned to the issuer 27,117 shares of Oncology InstituteSEC Form 415 November 2023Common stock · traded 14 November 2023 · filed 15 November 2023
- was granted 421,280 shares of Oncology Institute (a derivative holding)SEC Form 421 March 2023Non-Qualified Stock Option (right to buy) · traded 17 March 2023 · filed 21 March 2023
- was granted 168,512 shares of Oncology InstituteSEC Form 421 March 2023Common stock · traded 17 March 2023 · filed 21 March 2023
- ▼ sold on the open market 9,718 shares of Oncology InstituteSEC Form 422 November 2022Common Stock · traded 15 November 2022 · filed 22 November 2022
- was granted 525,188 shares of Oncology Institute (a derivative holding)SEC Form 421 November 2022Non-Qualified Stock Option (right to buy) · traded 17 November 2022 · filed 21 November 2022
- was granted 103,469 shares of Oncology InstituteSEC Form 421 November 2022Common Stock · traded 17 November 2022 · filed 21 November 2022
- returned to the issuer 9,718 shares of Oncology InstituteSEC Form 417 November 2022Common Stock · traded 15 November 2022 · filed 17 November 2022
- was granted 550,563 shares of Oncology Institute (a derivative holding)SEC Form 429 March 2022Stock Option (right to buy) · traded 21 March 2022 · filed 29 March 2022
- was granted 88,090 shares of Oncology Institute (a derivative holding)SEC Form 423 March 2022Stock Option (right to buy) · traded 21 March 2022 · filed 23 March 2022
- was granted 108,469 shares of Oncology InstituteSEC Form 423 March 2022Common stock · traded 21 March 2022 · filed 23 March 2022
- was granted 141,380 shares of Oncology InstituteSEC Form 418 November 2021Common Stock · traded 12 November 2021 · filed 18 November 2021
- was granted 212,070 shares of Oncology InstituteSEC Form 418 November 2021Common Stock · traded 12 November 2021 · filed 18 November 2021
- was granted 993,460 shares of Oncology Institute (a derivative holding)SEC Form 416 November 2021Stock Options (right to buy) · traded 12 November 2021 · filed 16 November 2021
- was granted 823,971 shares of Oncology Institute (a derivative holding)SEC Form 416 November 2021Stock Options (right to buy) · traded 12 November 2021 · filed 16 November 2021
- was granted 141,380 shares of Oncology InstituteSEC Form 416 November 2021Common Stock · traded 12 January 2021 · filed 16 November 2021
- was granted 212,070 shares of Oncology InstituteSEC Form 416 November 2021Common Stock · traded 12 January 2021 · filed 16 November 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.